The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
Researchers discover Clostridium difficile is evolving due to genetic changes that allow it to thrive on the Western diet and evade disinfectants making it highly adapted to spread in hospitals.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
In a study of healthy infants, researchers discover exposure to C. difficile in infancy may provide natural immunization later in childhood.
A new study has implicated the cytokine interferon gamma as a major contributor of blood–brain barrier breakdown in central nervous system infections.
Researchers from the University of Texas at Austin have passed an experimental RSV vaccine through Phase I human clinical trial with promising results.
Research suggests that in the UK, new cases of tick-borne Lyme disease could be three-times higher than previous estimates, possibly exceeding 8000 cases in 2019.
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
New research suggests that higher global temperatures could have prompted an adaptation in Candida auris, allowing it to infect warm-blooded mammals.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.